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Accepted 5 March 2010During pregnancy, maternal thrombocytopenia, platelet
count below 100 109/L, is often associated with gestational
thrombocytopenia, preeclampsia, systemic lupus eryth-
ematosus, immune thrombocytopenic purpura (ITP), drug-
induced thrombocytopenia, antiphospholipid antibody
syndrome, disseminated intravascualr coagulopathy, viral
infection, vitamin B12 or folic acid shortage, and hyper-
splenism. ITP is caused by autoantibodies targeting platelet
glycoprotein IIb/IIIa, Ib/IX, Ia/II, IV, and V. Antiplatelet
antibodies may induce platelet aggregation and precipitate
destruction of antibody-coated platelets by reticuloendothelial
uptake. ITP is diagnosed by exclusion, meaning that it is
diagnosed once other causes of thrombocytopenia are ruled
out. Herein, the successful management of a case of severe
ITP in a pregnant woman with inevitable preterm vaginal
breech delivery is presented.
A 28-year-old Gravida 1 woman who had chronic ITP and
was receiving regular follow-up at hematological clinics
visited our delivery room at 31 gestational weeks because of
preterm labor with a 2.5-cm dilation of cervical os, rupture of
the amniotic membrane, and breech presentation. Her dosage
of prednisolone had been increased from 20 mg/d to 30 mg/
d at 29 gestational weeks because of a low platelet count of
17 109/L. On this admission, laboratory examinations
revealed a platelet count of 30 109/L, a hemoglobin level of
11 g%, normal coagulation tests (prothrombin time and acti-
vated partial thromboplastin time), and no evidence of infec-
tion. Because she was going into active labor, she was given
two alternative doses of dexamethasone (12 mg, 12 hours
apart) to enhance fetal lung maturity and to treat maternal ITP.
A total of 15 g of intravenous immunoglobulin (IVIG) (TBSF;
CSL limited, Australia) was slowly administered (3 g each),
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delivery. Fourteen hours after admission, a 1,610 g healthy boy
was delivered by first intravenously administering nitroglyc-
erine (NTG) for uterine/cervical relaxation and then delivering
the fetal head with the use of Piper forceps. Apgar scores of
the newborn were 6 and 7 at 1 and 5 minutes, respectively. The
platelet count of the newborn was 174 109/L. Oxytocin,
methylergonovine, transamine, and misoprostol (0.8 mg, rectal
insertion) were given to prevent postpartum hemorrhage
(PPH). The patient lost about 400 cc of blood and withstood
the whole procedure very well. Unexpectedly, 90 minutes after
delivery she lost an additional 300 cc of blood in the recovery
room. Because the patient was not found to have retained
placenta and genital tract laceration during delivery, she was
given four units of vasopressin diluted to 100 cc and admin-
istered by injection into the uterine cervix, and she was also
intravenously administered 1.2 mg of recombinant activated
factor VII (Novo 7; Novo Nordisk, Denmark). This brought
her uterine bleeding under control. Abdominal sonography
revealed some blood clots, about 8 3 2 cm, in the uterine
cavity. She was prescribed oral misoprostol (0.2 mg/d) for 3
days and discharged in stable condition on postpartum Day 3.
Her clinical course is summarized in Table 1. To date, the
infant, currently 8 months old, has developed normally.
ITP is managed the same regardless of whether the patient
is pregnant or not. Prednisolone is often used as an initial
therapy with platelet counts ranging between 30 109/L and
50 109/L, depending on symptoms [1]. It is critical to avoid
unnecessary treatment of asymptomatic patients with mild-to-
moderate thrombocytopenia. Splenectomy, which can achieve
a 65% complete remission rate by decreasing destruction of
antibody-coated platelets and reducing antiplatelet antibody
production, is always reserved for patients who have serious
manifestations of ITP unresponsive to steroid therapy [2]. The
effect of IVIG occurs quickly and elicits a higher response rate
than steroid, making it a good alternative therapy for patients
resistant to steroids. A platelet count higher than 50 109/L is
considered safe for vaginal or cesarean delivery [3].cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Summary of the clinical course
Day 14 Labor, Day 1 Delivery, Day 0 PP Day 1 PP, Day 6 PP, Day 14
Platelet count 17 109/L 30 109/L 25 109/L 93 109/L 106 109/L 37 109/L
Transfusion Platelets, 1 unit, before delivery
Prednisolone 15 mg b.i.d. 15 mg b.i.d. 15 mg 15 mg b.i.d. 10 mg b.i.d. 10 mg b.i.d.
Dexamethasone 12 mg 12 mg (2 hr before delivery)
IVIG 9 g 6 g (finished 6 hr before delivery)
Delivery room NTG; Piper forceps
Blood loss 400 cc
Uterotonic, transamine
Recovery room 1.5 hr later, uterine bleeding 300 cc
vasopressin four units, novo 7 (1.2 mg)
b.i.d.¼ twice a day; IVIG¼ intravenous immunoglobulin; NTG¼ nitroglycerine; PP¼ postpartum.
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count to prevent major hemorrhage when patients are bleeding
or at risk of bleeding, rather than returning the platelet count to
normal [1]. Patients are potentially at risk of prolonged
bleeding after minor trauma when the platelet count is less
than 50 109/L [4]. Spontaneous bleeding may occur at
platelet counts between 20 109/L and 30 109/L. Life-
threatening bleeding, including intracranial bleeding, has
been reported at platelet counts below 10 109/L. Cortico-
steroids are effective in 75% of patients with ITP [4]. Platelet
counts usually begin to rise 3e7 days after the initiation of
prednisolone administration, reaching a maximal response in
2e3 weeks [5]. Eighty-five percent of those initially treated
with high-dose dexamethasone has been reported to achieve
a platelet count of 20 109/L by the third day and more than
50 109/L at 1 week [6]. Fifty percent of these responders can
maintain a platelet count of 50 109/L or more for 2e5 years
without additional treatment. Rituximab, which is an anti-
CD20 antibody, has been reported to be effective in refrac-
tory ITP [4] and seems safe for use during the third trimester
(Class C, Food and Drug Administration), although it may
temporarily inhibit neonatal B-cell development.
Pregnant women are at inevitable risk of bleeding during
delivery when episiotomy or cesarean section is performed or
when the placenta is separated from the uterus. Therefore, the
risk of PPH is increased when ITP is under poor control
(platelet count lower than 50 109/L) at delivery. IVIG may
be effective in raising the platelet count in 12e48 hours and
is useful when there is active bleeding or before emergency
surgical procedures [4,7]. Its effect may last for 2e3 weeks,
depending on the dose of IVIG and severity of ITP. The rec-
ommended dose of IVIG in the treatment of patients with ITP
is 1 g/kg/d for 1e2 days [8]. In view of the high cost of IVIG
and its potential side effects (severe headache, renal failure,
nephritis, and thrombosis) [4,9], a slow infusion rate and
a small dose, without compromising its effect, should be
considered. Although this patient had a low platelet count
(25 109/L), platelet count saved enough for vaginal breech
delivery was achieved with a low dose of IVIG (15 g)
combined with platelets transfusion. The transfused platelets,
binding to antiplatelet antibodies, are rapidly cleared by
reticuloendothelial system, and thus should be administeredimmediately before delivery [4]. Entrapment of fetal head,
although rare, is probably the most feared complication during
vaginal breech delivery. Most of those cases occur in preterm
fetuses less than 32 weeks of gestation. When the platelet count
is lower than 50 109/L, regional (epidural) anesthesia is
contraindicated [5]. NTG has been used to provide adequate
uterine/cervical relaxation for preventing entrapment of fetal
head during vaginal breech delivery. Because NTG has a very
short half-life (about 2 minutes), it does not increase postpartum
uterine bleeding. When NTG is administered and Piper forceps
are used in a timely manner, there is less uterine bleeding during
vaginal breech delivery than cesarean section. Cesarean section
should be reserved for obstetric indications in patients with ITP.
The fetal platelet count is unpredictable and does not correlate
withmaternal platelet count, the levels of antiplatelet antibodies,
ormaternal response to therapy. Four to five percent of newborns
have a platelet count less than 20 109/L and less than 1% will
have severe intracranial hemorrhage [8]. Most infants exposed
tomaternal ITP reach their platelet count nadir on the second day
of life, occasionally on Days 3e5. The complication rate of
cordocentesis (particularly of pregnancy loss and hematoma)
is 1e2%, possibly elevated in thrombocytopenic fetuses. In
pregnant women with ITP, the risk of cordocentesis exceeds the
benefit of determining the fetal platelet count, negating its
clinical usefulness. In addition, IVIG can cross placenta andmay
improve fetal platelet count by decreasing platelet destruction
[8], thus, making instrumental delivery safer and possibly
reducing the risk of neonatal intracranial hemorrhage.
The use of vasopressin in the obstetric field is less
mentioned [10]. When prostaglandin F2 alpha is not available,
a small dose of vasopressin, which is injected into uterine
cervix, may be considered as an alternative means of reducing
postpartum uterine hemorrhage as it causes vasoconstriction
and smooth muscle contraction. Its half-life is about 10e20
minutes. Intracervical injection is easily performed and can
deliver a high concentration of vasopressin at the low segment
of the uterus. Adverse effects of vasopressin, such as brady-
cardia or cardiac arrest, can be minimized by limiting a total
dose to no more than four units, a low concentration (0.2 units/
mL or less), and avoidance of inadvertent intravascular injec-
tion [11]. Recombinant activated factor VII, with a suggested
dose of 0.09 mg/kg, is being used more often to successfully
229F.-N. Cho / Taiwanese Journal of Obstetrics & Gynecology 50 (2011) 227e229manage life-threatening PPH because of coagulopathy or
uterine atony [12]. According to the result in this case study,
a small dose (1.2 mg) may effectively prevent deterioration of
PPH when IVIG and platelet transfusion have been performed.
Whether a small dose of recombinant activated factor VII can
be used as a prophylactic method in patients at high risk of
massive PPH deserves further investigation.
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